Table 2.
Demographics of healthy volunteers (pharmacokinetic analysis set) in six phase I studies investigating the clearance mechanisms, elimination, and potential for drug–drug interactions (DDIs) of vericiguat as a victim or perpetrator
| Characteristic | Human mass balance (n = 6) |
DDI with omeprazole and magnesium/aluminum hydroxide (n = 10) |
DDI with ketoconazole (n = 14) |
DDI with rifampicin (n = 15) |
DDI with mefenamic acid (n = 13) |
DDI with midazolam (n = 32) |
|---|---|---|---|---|---|---|
| Male, n (%) | 6 (100) | 10 (100) | 14 (100) | 15 (100) | 13 (100) | 32 (100) |
| White, n (%) | 6 (100) | 10 (100) | 14 (100) | 15 (100) | 13 (100) | 32 (100) |
| Age range criterion, years (inclusive) | 45–65 | 18–45 | 18–45 | 18–45 | 18–55 | 18–55 |
| Weight range, kg | 60.3–102.4 | 75.0–88.0 | 65–93 | 63.8–97.4 | 65–95 | 66.0–98.0 |
| Height range, cm | 167.0–192.0 | 172.0–186.0 | 171–190 | 171.0–191.0 | 166–187 | 167.0–198.0 |
| BMI range, kg/m2 | 19.1–29.0 | 21.7–28.7 | 20.1–28.8 | 19.5–28.5 | 19.3–29.0 | 20.8–29.8 |
Values are range (minimum–maximum) unless stated otherwise
BMI body mass index